

Maggi Webb
Transfusion Laboratory Manager
Northern Devon Healthcare Trust



Back to Basics

- History
- Immune response
- Rh (D) prophylaxis
- Estimation of fetal bleeds
- Common errors



Haemolytic disease of the newborn (HDN)

• A condition where the infant's red cells are prematurely destroyed by the action of specific antibodies in the maternal blood which cross the placenta during pregnancy.



 1609: The first description of a neonatal disease, almost certainly due to Rh HDN, can be found in the memoirs of a French midwife, Louise Bourgeois.





- 1939: Levine and Stetson showed that HDN was caused by an antibody in the maternal plasma.
- 1940: "Rh factor" discovered by Landsteiner and Weiner
- 1941: Levine et al tested the antibody against the parents of HDN infants
- 1945 Coombs, Mourant and Race showed that HDN was caused by maternal antibodies crossing the placenta



- 1956: It was shown that ABO incompatibility affords substantial protection against HDN
- 1969: First injection of Anti-D given
- 1971: First controlled trial of Anti-D given post delivery
- 1974: MRC working party reported on the trials and agreed the dose.



1969: post natal anti-D introduced

1976: extended to miscarriages and terminations

1981: sensitising events in pregnancy



Effectiveness of the program

1969 46 deaths in 100,000 births (HDN in 1% of neonates)

1.6 deaths in 100,000 births

But it was still occurring and shown to be following sensitising events in the third trimester

2002: RAADP introduced following NICE recommendation







THE IMMUNE RESPONSE



Primary antibody response


 Antibody usually detected 8-9 weeks after sensitisation

10-15% non responders10-15% very good responders

Weak IgM response followed by IgG

IgM antibodies cannot cross the placenta IgG antibodies can





Secondary antibody response

- Second exposure leads to rapid rise in IgG antibody level from 3 days
- Secondary response requires a small stimulation (<0.3ml)



Anti-D Prophylaxis Sensitising events

- Amniocentesis
- Cordocentesis
- Other in-utero therapeutic intervention
- Ante-partum haemorrhage
- Ectopic pregnancy
- External cephalic version
- Fall/abdominal trauma
- IUD
- Miscarriage
- Termination

Any sensitising effect should be considered for anti-D even after RAADP



Anti-D Prophylaxis RECURRENT BLEEDING

- <12 weeks probably not necessary</p>
- 12-20 weeks 250iu every 6 weeks
- > 20 weeks 500iu every 6 weeks + Kleihauer screen

Anti-D preparations available

250iu, 500iu and 1500iu

Minimum recommended dose is:

250iu before 20/40

500iu after 20/40

Routine ante-natal prophylaxis is either 1500iu at 28/40 or 500iu at 28/40 repeated at 34/40

Post-natal dose is 500iu as a routine.










Kleihauer film (Acid Elution)


- Good for screening and initial assessment
- Subjective





Not recommended as a test at <20 weeks Not suitable as a diagnostic test for a placental abruption


Flow cytometry

- Expensive
- More accurate
- Reference/confirmatory method
- Not always available to all labs quickly










Anti-D Prophylaxis PROBLEMS ENCOUNTERED

Differentiation between PAD and immune anti-D

Raised HbF due to pregnancy or genetic disorder







SHOT REPORT 2011

Type of event	Cases
 Omission/late administration 	157
 Given to Rh Pos woman 	30
• Given to woman with immune anti-D	17
• Given to mother of Rh Neg infant	9
 Given to wrong woman 	4
 Wrong dose given 	24
 Handling and storage errors 	8
Total	249



LEARNING POINT

Consider issuing anti-D on a named patient basis only

www.shotuk.org



SHOT REPORTS

- SHOT started 1996
- Recurrent themes include:
- Communication failures between hospital and community midwives
- Lack of a robust system for receiving anti-D Ig for RAADP
- Failure of the post-natal discharge checklist
- Poor advice from inexperienced laboratory staff
- Poor advice from midwives regarding the need for anti-D following sensitising events
- Failure by both lab and clinical staff to follow up women with positive antibody screens in pregnancy and an assumption that the result reflected PAD when in fact none had been given
- Inappropriate use of Kleihauer test to determine the need for anti-D



Anti-D Prophylaxis SHOT LEARNING POINTS

- Kleihauer test is used to determine if additional anti-D is required.....not whether anti-D is needed in the first place
- Interpretation of positive antibody screens in pregnancy must be the responsibility of senior laboratory staff and must take into account an accurate history
- Partnership between the laboratory and the clinical area.
 Clinicians must be more responsive to requests for follow up samples and the lab must not assume that actions have been taken purely because a report has been issued.



